R. Lee Douglas
Geen lopende functies
Profiel
R.
Lee Douglas was the founder of COR Therapeutics, Inc. (founded in 1988) where he held the titles of VP, Chief Executive & Financial Officer until 1998.
He was also the founder of Five Prime Therapeutics, Inc. (founded in 2002) where he held the title of Independent Director until 2017.
Mr. Douglas's former jobs include being a Director at Aerovance, Inc. and Calistoga Pharmaceuticals, Inc. He was also a Director at Affymax, Inc. from 2004 to 2011.
Mr. Douglas's education includes an undergraduate degree from The University of North Carolina at Charlotte and an MBA from Harvard Business School.
Eerdere bekende functies van R. Lee Douglas
Bedrijven | Functie | Einde |
---|---|---|
FIVE PRIME THERAPEUTICS, INC. | Oprichter | 10-05-2017 |
AFFYMAX, INC. | Directeur/Bestuurslid | 25-05-2011 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Oprichter | 01-01-1998 |
Aerovance, Inc.
Aerovance, Inc. Medical DistributorsDistribution Services Aerovance, Inc. develops drugs for respiratory and inflammatory diseases. The company was founded by Jeffrey Howard Tepper and Wolf-Dieter Busse in July 29, 2004 and is headquartered in Berkeley, CA. | Directeur/Bestuurslid | - |
Calistoga Pharmaceuticals, Inc.
Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Directeur/Bestuurslid | - |
Opleiding van R. Lee Douglas
The University of North Carolina at Charlotte | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AFFYMAX, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Calistoga Pharmaceuticals, Inc.
Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Health Technology |
Aerovance, Inc.
Aerovance, Inc. Medical DistributorsDistribution Services Aerovance, Inc. develops drugs for respiratory and inflammatory diseases. The company was founded by Jeffrey Howard Tepper and Wolf-Dieter Busse in July 29, 2004 and is headquartered in Berkeley, CA. | Distribution Services |